EU/3/10/838: Orphan designation for the treatment of post-essential thrombocythaemia myelofibrosis
Plitidepsin
Table of contents
Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor.
On 23 February 2011, orphan designation (EU/3/10/838) was granted by the European Commission to Pharma Mar S.A. Sociedad Unipersonal, Spain, for plitidepsin for the treatment of post-essential thrombocythaemia myelofibrosis.
Key facts
Active substance |
Plitidepsin
|
Intended use |
Treatment of post-essential thrombocythaemia myelofibrosis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/10/838
|
Date of designation |
23/02/2011
|
Sponsor |
Pharma Mar S.A. Sociedad Unipersonal
Avda. De los Reyes 1 Polígono Industrial La Mina 28770 Colmenar Viejo Madrid Spain Telephone: +34 91 846 60 00 Telefax: +34 91 823 60 01 pharmamar@pharmamar.com |
Review of designation
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor, before a marketing authorisation had been granted.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: